FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2541420108> ?p ?o ?g. }

• W2541420108 endingPage "55" @default.
• W2541420108 startingPage "48" @default.
• W2541420108 abstract "Purpose To establish whether maintenance lapatinib after first-line chemotherapy is beneficial in human epidermal growth factor receptor (HER) 1/HER2–positive metastatic urothelial bladder cancer (UBC). Methods Patients with metastatic UBC were screened centrally for HER1/HER2 overexpression. Patients who screened positive for HER1/2 and who did not have progressive disease during chemotherapy (four to eight cycles) were randomly assigned one to one to lapatinib or placebo after completion of first-line/initial chemotherapy for metastatic disease. The primary end point was progression-free survival (PFS). Results Between 2007 and 2013, 446 patients with UBC were screened, and 232 with HER1- or HER2-positive disease were randomly assigned. The median PFS for lapatinib and placebo was 4.5 (95% CI, 2.8 to 5.4) and 5.1 (95% CI, 3.0 to 5.8) months, respectively (hazard ratio, 1.07; 95% CI, 0.81 to 1.43; P = .63). The overall survival for lapatinib and placebo was 12.6 (95% CI, 9.0 to 16.2) and 12.0 (95% CI, 10.5 to 14.9) months, respectively (hazard ratio, 0.96; 95% CI, 0.70 to 1.31; P = .80). Discontinuation due to adverse events were similar in both arms (6% lapatinib and 5% placebo). The rate of grade 3 to 4 adverse events for lapatinib and placebo was 8.6% versus 8.1% ( P = .82). Preplanned subset analysis of patients strongly positive for HER1/HER2 (3+ on immunohistochemistry; n = 111), patients positive for only HER1 (n = 102), and patients positive for only HER2 (n = 42) showed no significant benefit with lapatinib in terms of PFS and overall survival ( P > .05 for each). Conclusion This trial did not find significant improvements in outcome by the addition of maintenance lapatinib to standard of care." @default.
• W2541420108 created "2016-11-04" @default.
• W2541420108 creator A5003521413 @default.
• W2541420108 creator A5006350937 @default.
• W2541420108 creator A5007496293 @default.
• W2541420108 creator A5009207957 @default.
• W2541420108 creator A5009861042 @default.
• W2541420108 creator A5012800133 @default.
• W2541420108 creator A5015032022 @default.
• W2541420108 creator A5022702970 @default.
• W2541420108 creator A5023529153 @default.
• W2541420108 creator A5031306593 @default.
• W2541420108 creator A5046905571 @default.
• W2541420108 creator A5047034789 @default.
• W2541420108 creator A5047234703 @default.
• W2541420108 creator A5048796030 @default.
• W2541420108 creator A5051243255 @default.
• W2541420108 creator A5076098983 @default.
• W2541420108 creator A5078099654 @default.
• W2541420108 creator A5079843750 @default.
• W2541420108 creator A5088951258 @default.
• W2541420108 date "2017-01-01" @default.
• W2541420108 modified "2023-10-16" @default.
• W2541420108 title "Phase III, Double-Blind, Randomized Trial That Compared Maintenance Lapatinib Versus Placebo After First-Line Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 1/2–Positive Metastatic Bladder Cancer" @default.
• W2541420108 cites W1519009312 @default.
• W2541420108 cites W1586024750 @default.
• W2541420108 cites W1968882012 @default.
• W2541420108 cites W1971208896 @default.
• W2541420108 cites W2012784647 @default.
• W2541420108 cites W2015918488 @default.
• W2541420108 cites W2022495797 @default.
• W2541420108 cites W2039814574 @default.
• W2541420108 cites W2054716056 @default.
• W2541420108 cites W2065671000 @default.
• W2541420108 cites W2114699723 @default.
• W2541420108 cites W2124010429 @default.
• W2541420108 cites W2136032744 @default.
• W2541420108 cites W2147609992 @default.
• W2541420108 cites W2152194109 @default.
• W2541420108 cites W2167319823 @default.
• W2541420108 cites W2341548114 @default.
• W2541420108 cites W2480921447 @default.
• W2541420108 doi "https://doi.org/10.1200/jco.2015.66.3468" @default.
• W2541420108 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28034079" @default.
• W2541420108 hasPublicationYear "2017" @default.
• W2541420108 type Work @default.
• W2541420108 sameAs 2541420108 @default.
• W2541420108 citedByCount "141" @default.
• W2541420108 countsByYear W25414201082017 @default.
• W2541420108 countsByYear W25414201082018 @default.
• W2541420108 countsByYear W25414201082019 @default.
• W2541420108 countsByYear W25414201082020 @default.
• W2541420108 countsByYear W25414201082021 @default.
• W2541420108 countsByYear W25414201082022 @default.
• W2541420108 countsByYear W25414201082023 @default.
• W2541420108 crossrefType "journal-article" @default.
• W2541420108 hasAuthorship W2541420108A5003521413 @default.
• W2541420108 hasAuthorship W2541420108A5006350937 @default.
• W2541420108 hasAuthorship W2541420108A5007496293 @default.
• W2541420108 hasAuthorship W2541420108A5009207957 @default.
• W2541420108 hasAuthorship W2541420108A5009861042 @default.
• W2541420108 hasAuthorship W2541420108A5012800133 @default.
• W2541420108 hasAuthorship W2541420108A5015032022 @default.
• W2541420108 hasAuthorship W2541420108A5022702970 @default.
• W2541420108 hasAuthorship W2541420108A5023529153 @default.
• W2541420108 hasAuthorship W2541420108A5031306593 @default.
• W2541420108 hasAuthorship W2541420108A5046905571 @default.
• W2541420108 hasAuthorship W2541420108A5047034789 @default.
• W2541420108 hasAuthorship W2541420108A5047234703 @default.
• W2541420108 hasAuthorship W2541420108A5048796030 @default.
• W2541420108 hasAuthorship W2541420108A5051243255 @default.
• W2541420108 hasAuthorship W2541420108A5076098983 @default.
• W2541420108 hasAuthorship W2541420108A5078099654 @default.
• W2541420108 hasAuthorship W2541420108A5079843750 @default.
• W2541420108 hasAuthorship W2541420108A5088951258 @default.
• W2541420108 hasBestOaLocation W25414201082 @default.
• W2541420108 hasConcept C121608353 @default.
• W2541420108 hasConcept C126322002 @default.
• W2541420108 hasConcept C141071460 @default.
• W2541420108 hasConcept C142724271 @default.
• W2541420108 hasConcept C143998085 @default.
• W2541420108 hasConcept C168563851 @default.
• W2541420108 hasConcept C203092338 @default.
• W2541420108 hasConcept C204787440 @default.
• W2541420108 hasConcept C207103383 @default.
• W2541420108 hasConcept C27081682 @default.
• W2541420108 hasConcept C2775930923 @default.
• W2541420108 hasConcept C2776694085 @default.
• W2541420108 hasConcept C2777329042 @default.
• W2541420108 hasConcept C2778283404 @default.
• W2541420108 hasConcept C2778715236 @default.
• W2541420108 hasConcept C2779786085 @default.
• W2541420108 hasConcept C44249647 @default.
• W2541420108 hasConcept C530470458 @default.
• W2541420108 hasConcept C71924100 @default.
• W2541420108 hasConcept C90924648 @default.
• W2541420108 hasConceptScore W2541420108C121608353 @default.
• W2541420108 hasConceptScore W2541420108C126322002 @default.

• next